# Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

> **NCT06175000** · PHASE2 · RECRUITING · sponsor: **Providence Health & Services** · enrollment: 28 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **PROCEDURE:** Cognitive Assessment
- **BIOLOGICAL:** Obinutuzumab
- **OTHER:** Quality of Life Assessment

## Key facts

- **NCT ID:** NCT06175000
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-13
- **Primary completion:** 2028-09-15
- **Final completion:** 2029-09-15
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06175000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06175000, "Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06175000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*